Skip to content

Dose-response relationship of intrathecal bupivacaine coadministered with different doses of sufentanil for cesarean section.

Dose-response relationship of intrathecal bupivacaine coadministered with different doses of sufentanil for cesarean section.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124175
Enrollment
Unknown
Registered
2026-05-08
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Control group:Simple bupivacaine for Intrathecal anesthesia
5ug sufentanil group:5ug sufentanil combined with bupivacaine for Intrathecal anesthesia
10ug sufentanil group:10ug sufentanil combined with bupivacaine for Intrathecal anesthesia

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients classified as ASA II; 2. Women with a single full-term pregnancy awaiting labor; 3. Individuals with no history of drug allergies or drug abuse; 4. Those who have signed the informed consent for combined spinal-epidural anesthesia.

Exclusion criteria

Exclusion criteria: 1. Pregnant women with pregnancy-induced hypertension, mild preeclampsia, severe preeclampsia, eclampsia, or hypotension; 2. Those with diabetes with pregnancy, gestational diabetes, pregnancy complicated with heart disease, or viral hepatitis; 3. Patients with a body mass index (BMI) >28 kg/m^2, excessively obese patients; 4. Pregnant women with coagulation disorders, respiratory diseases, contraindications to spinal anesthesia, preoperative medication use, mental disorders, or a history of opioid abuse; 5. Cases where fetal growth restriction, macrosomia, placenta previa, placental abruption, or premature rupture of membranes leads to fetal distress or stillbirth; 6. Pregnant women for whom anesthesia puncture fails or who do not cooperate during the procedure; 7. Those with spinal deformities or allergy to local anesthetics

Design outcomes

Primary

MeasureTime frame
The median effective dose and 95% effective dose of bupivacaine;

Secondary

MeasureTime frame
Vital signs of pregnant women (SBP, DBP, MAP, HR, SPO2) at corresponding time points;The incidence of adverse maternal events during the perioperative period (including but not limited to hypotension, hypertension; bradycardia, tachycardia; pruritus; dyspnea; chest tightness; pulling discomfort; nausea and vomiting; chills);1-minute and 5-minute Apgar scores of newborns;The occurrence time and recovery time of the movement-blocking sensation in pregnant women;

Countries

China

Contacts

Public ContactGuo Yanxia

Affiliated Hospital of North Sichuan Medical College

1240044860@qq.com+86 136 9829 9579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026